Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against Seres Therapeutics, Inc. (“Seres” or the “Company”) (Nasdaq: MCRB) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation concerns events surrounding the Company’s announcement on July 29, 2016 that its Phase 2 clinical study for ECOSPOR™ did not meet its primary endpoint of reducing the relative risk of Clostridium difficile infection recurrence. When this news was released, shares of Seres dropped in value sharply. Two days before the announcement, however, the Company’s President, CEO and Chairman of the Board sold 20,000 shares of Seres at a much higher price.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles dedicated to securing shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160801006286/en/